Notes:
The thromboembolic events in control patients from three prospective trials (AFASAK, SPAF and BAATAF) are combined and classified by severity. The thromboembolic complications associated with atrial fibrillation carry significant morbidity and mortality.

Note:
Intracranial events include all strokes and intracranial hemorrhages. Transient ischemic attacks and systemic emboli are not included. Control represents placebo in all studies except BAATAF where 46% of the “control” patients received aspirin and 54% received no treatment. Mild represents minimal or no disability. Moderate/severe represents moderate to severe disability. SPAF data are from group I only.

Back

Contents

Next

Acknowledgments:
The content of this presentation was prepared by Dr. Gregory Albers of the Stanford Stroke Center.